Classes
- ?????D01000144 | Second Faculty of Medicine
- Immunology in modern treatment and diagnosisD01000201 | Second Faculty of Medicine
- Clinical Immunology +2D0100039 | Second Faculty of Medicine
- Allergology and Clinical ImmunologyD0100139 | Second Faculty of Medicine
- Immunology +7D0105043 | Second Faculty of Medicine
- Clinical 10 days - Department of Immunology +1D0110IMU | Second Faculty of Medicine
- Alergology +3D060002 | Second Faculty of Medicine
- Laboratory Examination Methods +1D0601014 | Second Faculty of Medicine
- Laboratory Methods in Immunology +1D0601034 | Second Faculty of Medicine
- Summer Holidays Training +1D0602016 | Second Faculty of Medicine
Publications
- Complications of multiple myeloma-immune deficiency +12005 | Second Faculty of Medicine
- Chronic infection and immune deficiency2003 | Second Faculty of Medicine
- Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma2024 | Second Faculty of Medicine, Faculty of Physical Education and Sport, First Faculty of Medicine
- Oncostatin M and Nivolumab Affect the Cytotoxic T-Cell Proportions and the Susceptibility to TRAIL-Induced Death in Non-Leukocyte Cell Subpopulations in Soft Tissue Sarcomas2023 | Second Faculty of Medicine, Faculty of Physical Education and Sport, First Faculty of Medicine
- A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade2023 | Second Faculty of Medicine, First Faculty of Medicine
- Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies2023 | Second Faculty of Medicine
- News in immunology2023 | Second Faculty of Medicine
- The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective2023 | Second Faculty of Medicine
- Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy2023 | Second Faculty of Medicine
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial2022 | Second Faculty of Medicine, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
Loading network view...